Luxembourg, 26 November 2025

Environmental and Social Completion Sheet (ESCS)[1]

Overview

Project Name:	UCB INFLEXIO NEW MANUFACTURING PLANT AND R&D
Project Number:	2020-0708
Country:	Belgium
Project Description:	The project concerned investments in R&D activities in Europe, managed from UCB's central R&D organisation in Belgium, to advance the clinical development of two new monoclonal antibody drugs, bimekizumab (IL17A/F) and rozanolixizumab (FcRn) and the construction of a new advanced multiproduct manufacturing plant at UCB's existing Seveso site in Braine l'Alleud, Belgium, dedicated to the production of biologics.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

Environmental Assessment

The new plant fell under Annex II of the EIA Directive 2014/52/EU. Following a screening decision by the competent authorities (27/11/2018), a full EIA was not required due to the limited environmental impact anticipated from integrating the plant into the existing site. A detailed environmental study confirmed low, fully manageable impacts, with no effect on the nearby Natura 2000 site (BE31001).

Concerning the construction and operation of the plant, the project was executed without adverse environmental or social impacts. All required safety measures for worker health and security were implemented. The facility's design achieved best practice in water use and waste minimisation, and its CO_2 emissions (4562 tCO_2/year) are 28% lower than comparable biotech plants. The facility's design and operation set best practice benchmarks for water and waste management.

The Braine l'Alleud site is ISO 14001 certified. UCB's Biobank is registered with Belgian authorities and operates under stringent Standard Operational Procedures (SOPs) and regular audits. Animal experimentation complied with EU Directive 2010/63/EU and was minimised. The project is aligned with the Paris Agreement and UCB's Science Based Targets initiative for carbon neutrality by 2030.

No significant mitigation or compensation measures were required. The facility was successfully audited by the Belgian federal agency for medicines and health products (FAMHP), and process performance qualification was completed. No adaptive management measures were needed, and there are no residual impacts of concern.

[1] The template is for ILs and FLs

Luxembourg, 26 November 2025

Social Assessment

The project supported the market launch of innovative drugs targeting unmet medical needs, including rare/orphan diseases. Employment impacts were positive, with a net increase in site FTEs during construction and transition to operations. UCB's policy of internal transfers supported personal development, and the organisational model evolved to expand research and patient solutions teams in Belgium and Germany.

UCB maintains a clear governance structure and is committed to the UN Global Compact and Sustainable Development Goals. The company practices robust corporate social responsibility and operational health and safety management.

The project was implemented in line with all applicable EU directives. All E&S conditions and undertakings noted at appraisal were met, with no significant differences at completion. There were no material adverse environmental or social impacts, and no significant legal actions affecting operations.

Summary opinion of Environmental and Social aspects at completion:

Based on promoter reports, site visits, and monitoring, the EIB is of the opinion that the project was implemented in full compliance with national/EU legal frameworks. The project delivered its intended outcomes with best practice in environmental performance and positive social impact. No post-completion E&S monitoring is required beyond standard operational oversight.